Presentation is loading. Please wait.

Presentation is loading. Please wait.

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Published byRidwan Kartawijaya Modified over 5 years ago

Similar presentations

Presentation on theme: "Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in."— Presentation transcript:

1 Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials  Katsuyuki Hotta, MD, PhD, Yoshiro Fujiwara, MD, Katsuyuki Kiura, MD, PhD, Nagio Takigawa, MD, PhD, Masahiro Tabata, MD, PhD, Hiroshi Ueoka, MD, PhD, Mitsune Tanimoto, MD, PhD  Journal of Thoracic Oncology  Volume 2, Issue 5, Pages (May 2007) DOI: /01.JTO c7 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A flow chart of the progress of trials through the review.
Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO c7) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A: Association between objective response rate and median survival time in the first-line chemotherapy setting (p < ). B: Association between disease control rate and median survival time in the first-line chemotherapy setting (p < ). Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO c7) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A: Association between objective response rate and median survival time in the second-line or later chemotherapy setting (p = ). B: Association between disease control rate and median survival time in the second-line or later chemotherapy setting p = ). Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO c7) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Radiation Necrosis Mimicking Progressive Brain Metastasis in a Patient with Non-small Cell Lung Cancer  Kadoaki Ohashi, MD, Kastuyuki Kiura, MD, PhD,

Radiation Necrosis Mimicking Progressive Brain Metastasis in a Patient with Non-small Cell Lung Cancer  Kadoaki Ohashi, MD, Kastuyuki Kiura, MD, PhD,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing.

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian.

Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Similar presentations

Ads by Google